Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
| ▸ | CYP21A2 | P08686 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | AXL | P30530 | 6/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.32 |
| ▸ | TNK1 | Q13470 | 1/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4008649 | 0.85 | ALDH1A1 (0.40) | KDM4EALDH1A1POLBFAAH | |
| SCHEMBL3746430 | 0.79 | NAMPT (0.35) | KDM4ENAMPTAXLPARP1TNK2 | |
| SCHEMBL402319 | 0.72 | CYP1A2 (0.44) | NAMPTMAP4K4ALDH1A1 | |
| SCHEMBL4004740 | 0.72 | PRKAA2 (0.41) | FAAH | |
| SCHEMBL4007633 | 0.71 | CCR3 (0.41) | — | |
| SCHEMBL4241314 | 0.69 | NAMPT (0.49) | KDM4ENAMPT | |
| SCHEMBL23573813 | 0.69 | PIK3CA (0.47) | KDM4EMAP4K4AXL | |
| SCHEMBL23573859 | 0.69 | KDM4E (0.43) | KDM4EALDH1A1 | |
| SCHEMBL398486 | 0.67 | KDR (0.43) | MAP4K4ALDH1A1POLBFAAH | |
| SCHEMBL401863 | 0.67 | KCNQ3 (0.40) | KDM4ENAMPTALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198203-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED | 2021-07-01 | — | — | US | claimed |
| US-20190352267-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED | 2019-11-21 | — | — | US | claimed |
| US-20180305316-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED | 2018-10-25 | — | — | US | claimed |
| EP-2862859-A2 | Compounds, compositions and methods | Cytokinetics, Inc. (US) | 2015-04-22 | — | — | EP | claimed |
| US-20150005296-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED | 2015-01-01 | — | — | US | claimed |
| EP-1765327-A4 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS INC (US) | 2009-06-17 | — | — | EP | claimed |
| US-20090036447-A1 | Compounds, Compositions and Methods | CYTOKINETICS, INC. (US) | 2009-02-05 | — | — | US | claimed |
| EP-1765327-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2007-03-28 | — | — | EP | claimed |
| WO-2006009726-A2 | SUBSTITUTED UREA DERIVATIVES FOR TREATING CARDIAC DISEASES | CYTOKINETICS, INC. (US) | 2006-01-26 | — | — | WO | claimed |
| US-20060014761-A1 | Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate | CYTOKINETICS, INCORPORATED | 2006-01-19 | — | — | US | claimed |
| US-12264133-B2 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED (US) | 2025-04-01 | — | — | US | disclosed |
| US-20220185779-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED | 2022-06-16 | — | — | US | disclosed |
| US-20210198203-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED | 2021-07-01 | — | — | US | disclosed |
| US-10975034-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| US-20190352267-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED | 2019-11-21 | — | — | US | disclosed |
| US-20070161617-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2007-07-12 | — | — | US | disclosed |
| WO-2007070683-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| EP-1765327-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006009726-A2 | SUBSTITUTED UREA DERIVATIVES FOR TREATING CARDIAC DISEASES | CYTOKINETICS, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
| US-20060014761-A1 | Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate | CYTOKINETICS, INCORPORATED | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161617-A1 | Certain chemical entities, compositions and methods | TNNI3, TNNT2, MYLK2 | KDM4E 2547/4885NAMPT 3645/4885MAP4K4 1580/4885 |
| US-20060014761-A1 | Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate | TNNI3, MYLK2, TNNT2 | KDM4E 774/4885NAMPT 4088/4885MAP4K4 593/4885 |
| US-20220185779-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TNNI3, TNNC1, TNNT2 | KDM4E 2421/4885NAMPT 3383/4885MAP4K4 1698/4885 |
| US-12264133-B2 | Compounds, compositions and methods | TNNI3, TNNC1, TNNT2 | KDM4E 2421/4885NAMPT 3383/4885MAP4K4 1698/4885 |
| US-20190352267-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TNNI3, TNNC1, TNNT2 | KDM4E 2421/4885NAMPT 3383/4885MAP4K4 1698/4885 |
| US-20150005296-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TNNI3, TNNC1, TNNT2 | KDM4E 2421/4885NAMPT 3383/4885MAP4K4 1698/4885 |
| US-10975034-B2 | Compounds, compositions and methods | TNNI3, TNNC1, TNNT2 | KDM4E 2421/4885NAMPT 3383/4885MAP4K4 1698/4885 |
| US-20090036447-A1 | Compounds, Compositions and Methods | TNNI3, TNNC1, TNNT2 | KDM4E 2421/4885NAMPT 3383/4885MAP4K4 1698/4885 |
| US-20180305316-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TNNI3, TNNC1, TNNT2 | KDM4E 2421/4885NAMPT 3383/4885MAP4K4 1698/4885 |
| US-20210198203-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TNNI3, TNNC1, TNNT2 | KDM4E 2421/4885NAMPT 3383/4885MAP4K4 1698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.